Psychoneuroendocrinology
July 1, 2025
Ece Idil, Bahar Yuksel, Zeynep Sen et al.
2 citations
Ketamine is a rapid-acting antidepressant with sexually dimorphic effects. Female animals exhibit a higher sensitivity to its antidepressant properties, which has been associated with their ovarian hormone levels. One factor contributing to this sex difference is the faster rate of ketamine metabolism observed in females, potentially regulated by estrogen receptor alpha (ERα) through modulation...
Current Oncology
June 30, 2025
Haley D M Schuman, Chantal Savard, Raèf Mina et al.
9 citations
This systematic review and meta-analysis evaluates (1) the effectiveness of psychedelic-assisted therapy (PAT) using psilocybin and ketamine for psychosocial symptoms in adults with cancer, (2) contextualizes findings with non-randomized and exploratory studies of other psychedelics, and (3) examines the role of therapeutic frameworks in shaping outcomes. We searched PubMed, Cochrane Library,...
Journal of Psychopharmacology
June 30, 2025
Jess Kerr-Gaffney, Anna Tröger, Alice Caulfield et al.
6 citations
Ketamine has emerged as a putative rapid-acting treatment option for psychiatric disorders, particularly treatment-resistant depression. Chronic recreational ketamine use is associated with ketamine-induced urological toxicity, raising concerns over the safety of repeated ketamine treatments. This systematic review aimed to synthesise urological findings from clinical trials and observational...
Molecules
June 30, 2025
Ewa Gibuła-Tarłowska, Anna Wiszniewska, Magdalena Turyk et al.
10 citations
Ketamine, originally developed as an anesthetic, is gaining increasing attention due to its multifaceted pharmacological properties. In addition to its use in anesthesia, ketamine exerts potent analgesic effects via N-methyl-D-aspartate (NMDA) receptor antagonism, modulating pain perception and reducing central sensitization, particularly in chronic and neuropathic pain conditions. Emerging...
Cureus
June 24, 2025
Alfred Mathew, Roshan Dongre, Seo Hee Kim et al.
The coronavirus variant (causing the COVID-19 disease) that led to a pandemic sent global shockwaves, resulting in long-term effects on physical, mental, and social well-being and impacting both individuals and communities. With the pandemic's notable impact on mental health, one such potential treatment discussed in recent literature is psilocybin. Psilocybin is a naturally occurring prodrug...
Supportive Care in Cancer
June 24, 2025
Ana Ferrigno Guajardo, Misael Salazar-Alejo, Fernanda Mesa-Chavez et al.
3 citations
This study evaluated the efficacy of an online mindfulness-based stress reduction (MBSR) intervention in reducing anxiety among breast cancer (BC) survivors, leveraging the potential advantages of digital delivery to enhance psychosocial care for this population. In this randomized controlled trial, 68 BC survivors with elevated anxiety levels were assigned to either an 8-week online MBSR...
European Neuropsychopharmacology
June 23, 2025
Jessica S. Henry, Bruna Giribaldi, David Nutt et al.
2 citations
Patients with Major Depressive Disorder (MDD) have more dysfunctional attitudes than healthy individuals and these pessimistic biases are correlated with depression severity. Psilocybin has demonstrated sustained remission in depression. Secondary analysis of a two-arm randomized controlled trial assessing the effect of psilocybin therapy versus escitalopram on 'maladaptive' cognitive biases...
Journal of Affective Disorders
June 18, 2025
Julia Myerson, Katrina A Rufino, Sanjay J. Mathew et al.
Electroconvulsive therapy (ECT) and intravenous (IV) ketamine are treatments used for severe depression and/or treatment-resistant depression (TRD). ECT is considered one of the most effective treatments for severe depression, although there is debate within the field regarding the effectiveness between ECT and IV ketamine in comparable TRD patient groups. This retrospective chart review of...
Journal of Psychoactive Drugs
June 18, 2025
Rafaelle Lancelotta, Meghan DellaCrosse, Diana Quinn et al.
7 citations
This study investigated subjective psychedelic experiences in the global LGBTQIA+ population. Using validated measures of acute psychedelic effects, psychological flexibility, gender and sexual identity attitudes, adverse experiences, and mental health, we examined self-reported changes in identity and mental health outcomes following psychedelic use. A total of 346 individuals completed the...
Journal of Medicinal Chemistry
June 18, 2025
Alexandra Sink, Eline Pottie, Samuel J Carter et al.
2 citations
The serotonin 2A receptor (5-HT2AR) modulates various neurotransmitter systems and is implicated in psychiatric disorders, including depression and schizophrenia. Despite progress, the detailed mechanisms of signaling at the 5-HT2AR and its therapeutic implications remain unclear, warranting further exploration. Overcoming the limitations of conventional pharmacology, photopharmacology...